- Home
- COAG
as of 08-14-2026 3:44pm EST
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.4B | IPO Year: | 2026 |
| Target Price: | N/A | AVG Volume (30 days): | 405.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.47 - $55.18 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -17.98 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K Aug 11, 2026
Q2 2026 Earnings
8-KAug 11, 2026
2026 Q1 Q1 2026 Earnings
8-K May 21, 2026
Q1 2026 Earnings
8-KMay 21, 2026
Compare COAG vs Leading Stocks
See how COAG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COAG Hemab Therapeutics Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.